First Week of Q3 Earnings in the Books
The Dow looks to close higher for its second-straight week, while the Nasdaq hopes to avoid its worst trading week since July.
Zacks Investment Research10/16/2026Negative
ISRG
Intuitive Surgical IncNASDAQHEALTHCAREMEDICAL INSTRUMENTS & SUPPLIES
Key Statistics
Market Cap
$150.74B
P/E Ratio
48.93
EPS
$8.72
Beta
1.46
52W High
$603.88
52W Low
$328.57
50-Day MA
$391.67
200-Day MA
$439.63
Dividend Yield
—
Profit Margin
28.40%
Forward P/E
33.33
PEG Ratio
1.87
About Intuitive Surgical Inc
Intuitive Surgical, Inc. is an American corporation that develops, manufactures, and markets robotic products designed to improve clinical outcomes of patients through minimally invasive surgery, most notably with the da Vinci Surgical System.
Fundamentals
| Revenue (TTM) | $11.03B |
| Gross Profit (TTM) | $7.36B |
| EBITDA | $4.18B |
| Operating Margin | 33.60% |
| Return on Equity | 17.40% |
| Return on Assets | 10.50% |
| Revenue/Share (TTM) | $31.07 |
| Book Value | $51.34 |
| Price-to-Book | 7.82 |
| Price-to-Sales (TTM) | 13.66 |
| EV/Revenue | 12.4 |
| EV/EBITDA | 32.23 |
| Quarterly Earnings Growth (YoY) | 26.50% |
| Quarterly Revenue Growth (YoY) | 18.50% |
| Shares Outstanding | $353.28M |
| Float | $351.21M |
| % Insiders | 0.51% |
| % Institutions | 89.56% |
Historical Volatility
HV 10-Day
24.85%
HV 20-Day
25.31%
HV 30-Day
28.16%
HV 60-Day
32.62%
HV Rank
40.5%
Volatility is currently contracting
Analyst Ratings
Consensus ($478.53 target)
7
Strong Buy17
Buy7
Hold1
SellLatest News
ISRG Ahead of Q3 Earnings: Can Procedure Growth Sustain Momentum?
Intuitive Surgical's Q3 earnings hinge on robotic surgery growth, system demand and margins amid slowing US procedures, China headwinds and premium valuation.
Zacks Investment Research10/16/2026Negative
Intuitive Surgical, Inc. (ISRG) Beats Stock Market Upswing: What Investors Need to Know
Intuitive Surgical, Inc. (ISRG) reached $427.86 at the closing of the latest trading day, reflecting a +1.81% change compared to its last close.
Zacks Investment Research10/15/2026Positive
Countdown to Intuitive Surgical (ISRG) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
Evaluate the expected performance of Intuitive Surgical (ISRG) for the quarter ended September 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Zacks Investment Research10/15/2026Neutral
ISRG Gains Nearly 12% in a Month: Should You Buy, Hold or Sell?
Intuitive Surgical shares have surged nearly 12% in a month ahead of Q3 earnings. Strong da Vinci 5 adoption and Ion growth fuel momentum, but valuation and risks linger.
Zacks Investment Research10/14/2026Positive
ISRG Is Expanding Beyond Surgery: Here's Why the GI Opportunity Matters
Intuitive Surgical is targeting GI care with a next-generation robotic endoscope submitted to the FDA, opening a potential growth avenue beyond surgery.
Zacks Investment Research10/13/2026Positive
Intuitive Surgical (ISRG) Upgraded to Buy: Here's Why
Intuitive Surgical (ISRG) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks Investment Research10/13/2026Positive
3 Sales Growth Stocks to Buy as Q3 Earnings Get Underway
Chipotle, BP and Intuitive Surgical stand out for strong sales growth, solid cash flow and favorable valuation metrics as Q3 earnings begin.
Zacks Investment Research10/13/2026Positive
Investors Heavily Search Intuitive Surgical, Inc. (ISRG): Here is What You Need to Know
Intuitive Surgical (ISRG) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Zacks Investment Research10/13/2026Positive
Is Intuitive Surgical (ISRG) a Buy as Wall Street Analysts Look Optimistic?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Zacks Investment Research10/8/2026Neutral
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ISRG and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 10/17/2026